SPONSOR
GlaxoSmithKline
Total Trials
17
Recruiting
17
Phases
Phase 3, Phase 1, Phase 1, Phase 2, Phase 2, Phase 2, Phase 3, Phase 4
Conditions studied: Nasal PolypsUrinary Tract InfectionsChickenpoxNeoplasms, LungAsthmaMultiple MyelomaMalaria, FalciparumSystemic Sclerosis Associated Interstitial Lung DiseaseScleroderma, SystemicPulmonary Disease, Chronic Obstructive
GlaxoSmithKline is a clinical research sponsor with 17 registered studies on ClinicalTrials.gov, of which 17 are actively recruiting participants. Research covers conditions including Nasal Polyps, Urinary Tract Infections, Chickenpox, Neoplasms, Lung.
The trial portfolio spans Phase 3, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — GlaxoSmithKline
How many clinical trials has GlaxoSmithKline sponsored?
ClinicalMetric currently tracks 17 clinical trials sponsored by GlaxoSmithKline, of which 17 are actively recruiting participants. These trials cover conditions including Nasal Polyps, Urinary Tract Infections, Chickenpox. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does GlaxoSmithKline research focus on?
GlaxoSmithKline clinical trials span Nasal Polyps, Urinary Tract Infections, Chickenpox, Neoplasms, Lung, Asthma, and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a GlaxoSmithKline clinical trial?
To participate in a GlaxoSmithKline trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all GlaxoSmithKline trials with current recruitment status updated daily.
Clinical Trials by GlaxoSmithKline
NCT07782957 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Nasal Polyps
NCT07645235 Phase 1
Recruiting
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women
Urinary Tract Infections
NCT06740630 Phase 3
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Chickenpox
NCT07602855 Phase 1, Phase 2
Recruiting
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Neoplasms, Lung
NCT07645248 Phase 3
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
Asthma
NCT07227311 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
NCT07545681 Phase 2
Recruiting
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
Malaria, Falciparum
NCT05878717 Phase 2, Phase 3
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Systemic Sclerosis Associated Interstitial Lung Disease
NCT06702449 Phase 1, Phase 2
Recruiting
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
Urinary Tract Infections
NCT07782996 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
Asthma
NCT07780656 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Pulmonary Disease, Chronic Obstructive
NCT07502560 Phase 4
Recruiting
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
Herpes Zoster
NCT07456033 Phase 3
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
Asthma
NCT06256588 Phase 3
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Neoplasms, Head and Neck
NCT07099898 Phase 3
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Neoplasms, Lung
NCT07747480 Phase 1
Recruiting
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis
Colitis, Ulcerative
NCT07224672 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Amyloidosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology